Authors

Vladimir Novitsky, Harvard University; Botswana-Harvard AIDS Institute Partnership
Rui Wang, Harvard University
Hermann Bussmann, Harvard University; Botswana-Harvard AIDS Institute Partnership
Shahin Lockman, Harvard University; Botswana-Harvard AIDS Institute Partnership
Marianna K. Baum, Department of Dietetics and Nutrition, Florida International UniversityFollow
Roger Shapiro, Harvard University; Botswana-Harvard AIDS Institute Partnership
Ibou Thior, Harvard University; Botswana-Harvard AIDS Institute Partnership
Carolyn Wester, Harvard University; Botswana-Harvard AIDS Institute PartnershipFollow
C. William Wester, Harvard University; Botswana-Harvard AIDS Institute Partnership ; Venderbilt UniversityFollow
Anthony Ogwu, Harvard University; Botswana-Harvard AIDS Institute Partnership
Aida Asmelash, Harvard University; Botswana-Harvard AIDS Institute Partnership
Rosemary Musonda, Harvard University; Botswana-Harvard AIDS Institute Partnership
Adriana Campa, Department of Dietetics and Nutrition, Florida International UniversityFollow
Sikhulile Moyo, Botswana-Harvard AIDS Institute Partnership
Erik van Widenfelt, Botswana-Harvard AIDS Institute Partnership
Madisa Mine, Botswana-Harvard AIDS Institute Partnership
Claire Moffat, Harvard University; Botswana-Harvard AIDS Institute Partnership
Mompati Mmalane, Botswana-Harvard AIDS Institute Partnership
Joseph Makhema, Harvard University; Botswana-Harvard AIDS Institute Partnership
Richard Marlink, Harvard University; Botswana-Harvard AIDS Institute Partnership
Peter Gilbert, University of Washington
George R. Seage III, Harvard University
Victor DeGruttola, Harvard University
M. Essex, Harvard University; Botswana-Harvard AIDS Institute Partnership

Date of this Version

4-12-2010

Document Type

Article

Abstract

The first aim of the study is to assess the distribution of HIV-1 RNA levels in subtype C infection. Among 4,348 drug-naı¨ve HIV-positive individuals participating in clinical studies in Botswana, the median baseline plasma HIV-1 RNA levels differed between the general population cohorts (4.1–4.2 log10) and cART-initiating cohorts (5.1–5.3 log10) by about one log10. The proportion of individuals with high ($50,000 (4.7 log10) copies/ml) HIV-1 RNA levels ranged from 24%–28% in the general HIV-positive population cohorts to 65%–83% in cART-initiating cohorts. The second aim is to estimate the proportion of individuals who maintain high HIV-1 RNA levels for an extended time and the duration of this period. For this analysis, we estimate the proportion of individuals who could be identified by repeated 6- vs. 12-month-interval HIV testing, as well as the potential reduction of HIV transmission time that can be achieved by testing and ARV treating. Longitudinal analysis of 42 seroconverters revealed that 33% (95% CI: 20%–50%) of individuals maintain high HIV-1 RNA levels for at least 180 days post seroconversion (p/s) and the median duration of high viral load period was 350 (269; 428) days p/s. We found that it would be possible to identify all HIV-infected individuals with viral load $50,000 (4.7 log10) copies/ml using repeated six-month-interval HIV testing. Assuming individuals with high viral load initiate cART after being identified, the period of high transmissibility due to high viral load can potentially be reduced by 77% (95% CI: 71%–82%). Therefore, if HIV-infected individuals maintaining high levels of plasma HIV-1 RNA for extended period of time contribute disproportionally to HIV transmission, a modified ‘‘test-and-treat’’ strategy targeting such individuals by repeated HIV testing (followed by initiation of cART) might be a useful public health strategy for mitigating the HIV epidemic in some communities.

Creative Commons License

Creative Commons Attribution 3.0 License
This work is licensed under a Creative Commons Attribution 3.0 License.

Share

COinS
 

Rights Statement

Rights Statement

In Copyright. URI: http://rightsstatements.org/vocab/InC/1.0/
This Item is protected by copyright and/or related rights. You are free to use this Item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s).